Vanessa D. Redecke, MD, PhD

Languages

  • English

Academic Information

  • Departments: Pathology - Research Assistant Professor
  • Divisions: Microbiology and Immunology

Email: Vanessa.Redecke@path.utah.edu

Education History

Type School Degree
Postdoctoral Training University of California, San Diego School of Medicine
Postdoctoral Researcher
Residency Technical University Munich School of Medicine
Medical Microbiology, Immunology and Hygiene
Resident
Doctoral Training University of Lübeck Medical School
Medicine and Medical Microbiology
Ph.D.
Residency Technical University Munich School of Medicine
Internal Medicine
Resident
Professional Medical University of Lübeck Medical School
Medicine
M.D.

Global Impact

Education History

Type School Degree Country
Residency Technical University Munich School of Medicine
Medical Microbiology, Immunology and Hygiene
Resident Germany
Doctoral Training University of Lübeck Medical School
Medicine and Medical Microbiology
Ph.D. Germany
Residency Technical University Munich School of Medicine
Internal Medicine
Resident Germany
Professional Medical University of Lübeck Medical School
Medicine
M.D. Germany

Selected Publications

Journal Article

  1. Kuriakose J, Redecke V, Guy C, Zhou J, Wu R, Ippagunta SK, Tillman H, Walker PD, Vogel P, Hacker H (2019). Patrolling monocytes promote the pathogenesis of early lupus-like glomerulonephritis.LID - 10.1172/JCI125116 [doi]LID - 125116 [pii]. J Clin Invest, 130.
  2. Pollock JA, Sharma N, Ippagunta SK, Redecke V, Hacker H, Katzenellenbogen JA (2018). Triaryl Pyrazole Toll-Like Receptor Signaling Inhibitors: Structure-Activity Relationships Governing Pan- and Selective Signaling Inhibitors. ChemMedChem, 13(20), 2208-2216.
  3. Ippagunta SK, Pollock JA, Sharma N, Lin W, Chen T, Tawaratsumida K, High AA, Min J, Chen Y, Guy RK, Redecke V, Katzenellenbogen JA, Hacker H (2018). Identification of Toll-like receptor signaling inhibitors based on selective activation of hierarchically acting signaling proteins.LID - eaaq1077 [pii]LID - 10.1126/scisignal.aaq1077 [doi]. Sci Signal, 11(543).
  4. Ippagunta SK, Gangwar R, Finkelstein D, Vogel P, Pelletier S, Gingras S, Redecke V, Hacker H (2016). Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1 function. Proc Natl Acad Sci U S A, 113(41), E6162-E6171.
  5. Redecke V, Chaturvedi V, Kuriakose J, Hacker H (2016). SHARPIN controls the development of regulatory T cells. Immunology, 148(2), 216-26.
  6. Tawaratsumida K, Phan V, Hrincius ER, High AA, Webby R, Redecke V, Hacker H (2014). Quantitative proteomic analysis of the influenza A virus nonstructural proteins NS1 and NS2 during natural cell infection identifies PACT as an NS1 target protein and antiviral host factor. J Virol, 88(16), 9038-48.
  7. Redecke V, Wu R, Zhou J, Finkelstein D, Chaturvedi V, High AA, Hacker H (2013). Hematopoietic progenitor cell lines with myeloid and lymphoid potential. Nat Methods, 10(8), 795-803.
  8. LeMessurier KS, Hacker H, Chi L, Tuomanen E, Redecke V (2013). Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathog, 9(11), e1003727.
  9. Zhou J, Wu R, High AA, Slaughter CA, Finkelstein D, Rehg JE, Redecke V, Hacker H (2011). A20-binding inhibitor of NF-kappaB (ABIN1) controls Toll-like receptor-mediated CCAAT/enhancer-binding protein beta activation and protects from inflammatory disease. Proc Natl Acad Sci U S A, 108(44), E998-1006.
  10. Stempin CC, Chi L, Giraldo-Vela JP, High AA, Hacker H, Redecke V (2011). The E3 ubiquitin ligase mind bomb-2 (MIB2) protein controls B-cell CLL/lymphoma 10 (BCL10)-dependent NF-kappaB activation. J Biol Chem, 286(43), 37147-57.
  11. LeMessurier K, Hacker H, Tuomanen E, Redecke V (2010). Inhibition of T cells provides protection against early invasive pneumococcal disease. Infect Immun, 78(12), 5287-94.
  12. Hacker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Hacker G, Mann M, Karin M (2006). Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature, 439(7073), 204-7.
  13. Schmidt R, Redecke V, Breitfeld Y, Wantia N, Miethke T, Massberg S, Fischel S, Neumann FJ, Schomig A, May AE (2006). EMMPRIN (CD 147) is a central activator of extracellular matrix degradation by Chlamydia pneumoniae-infected monocytes. Implications for plaque rupture. Thromb Haemost, 95(1), 151-8.
  14. Hayashi T, Gong X, Rossetto C, Shen C, Takabayashi K, Redecke V, Spiegelberg H, Broide D, Raz E (2005). Induction and inhibition of the Th2 phenotype spread: implications for childhood asthma. J Immunol, 174(9), 5864-73.
  15. Ju XS, Hacker C, Scherer B, Redecke V, Berger T, Schuler G, Wagner H, Lipford GB, Zenke M (2004). Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation. Gene, 331, 159-64.
  16. Redecke V, Hacker H, Datta SK, Fermin A, Pitha PM, Broide DH, Raz E (2004). Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol, 172(5), 2739-43.
  17. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, Raz E, Cottam HB (2003). Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc Natl Acad Sci U S A, 100(11), 6646-51.
  18. May AE, Redecke V, Gruner S, Schmidt R, Massberg S, Miethke T, Ryba B, Prazeres da Costa C, Schomig A, Neumann FJ (2003). Recruitment of Chlamydia pneumoniae-infected macrophages to the carotid artery wall in noninfected, nonatherosclerotic mice. Arterioscler Thromb Vasc Biol, 23(5), 789-94.
  19. Datta SK, Redecke V, Prilliman KR, Takabayashi K, Corr M, Tallant T, DiDonato J, Dziarski R, Akira S, Schoenberger SP, Raz E (2003). A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J Immunol, 170(8), 4102-10.
  20. Prebeck S, Kirschning C, Durr S, da Costa C, Donath B, Brand K, Redecke V, Wagner H, Miethke T (2001). Predominant role of toll-like receptor 2 versus 4 in Chlamydia pneumoniae-induced activation of dendritic cells. J Immunol, 167(6), 3316-23.
  21. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB (2001). Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A, 98(16), 9237-42.
  22. Bauer M, Redecke V, Ellwart JW, Scherer B, Kremer JP, Wagner H, Lipford GB (2001). Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol, 166(8), 5000-7.
  23. Redecke V, Dalhoff K, Bohnet S, Braun J, Maass M (1998). Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response. Am J Respir Cell Mol Biol, 19(5), 721-7.

Review

  1. Horner AA, Redecke V, Raz E (2004). Toll-like receptor ligands: hygiene, atopy and therapeutic implications. [Review]. Current Opinion in Allergy and Clinical Immunology, 4(6), 555-61.
  2. Hcker G, Redecke V, Hcker H (2002). Activation of the immune system by bacterial CpG-DNA. [Review]. Immunology, 105, 245-51.

Patent

  1. Redecke V (2004). TLR2 agonists for treatment of Th1 associated immunopathological disorders.